TW202306570A - 3-(5-氧基)-1-側氧基異吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 - Google Patents
3-(5-氧基)-1-側氧基異吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 Download PDFInfo
- Publication number
- TW202306570A TW202306570A TW111120484A TW111120484A TW202306570A TW 202306570 A TW202306570 A TW 202306570A TW 111120484 A TW111120484 A TW 111120484A TW 111120484 A TW111120484 A TW 111120484A TW 202306570 A TW202306570 A TW 202306570A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- hydrate
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196422P | 2021-06-03 | 2021-06-03 | |
| US63/196,422 | 2021-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202306570A true TW202306570A (zh) | 2023-02-16 |
Family
ID=82115547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111120484A TW202306570A (zh) | 2021-06-03 | 2022-06-01 | 3-(5-氧基)-1-側氧基異吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12103919B2 (https=) |
| EP (1) | EP4347580A1 (https=) |
| JP (1) | JP2024520654A (https=) |
| KR (1) | KR20240013812A (https=) |
| CN (1) | CN117062811A (https=) |
| AR (1) | AR126052A1 (https=) |
| AU (1) | AU2022284366A1 (https=) |
| BR (1) | BR112023024905A2 (https=) |
| CA (1) | CA3215410A1 (https=) |
| CL (1) | CL2023003561A1 (https=) |
| CO (1) | CO2024000013A2 (https=) |
| CR (1) | CR20230614A (https=) |
| DO (1) | DOP2023000261A (https=) |
| EC (1) | ECSP24000004A (https=) |
| IL (1) | IL308094A (https=) |
| JO (1) | JOP20230308A1 (https=) |
| MX (1) | MX2023014327A (https=) |
| PE (1) | PE20240657A1 (https=) |
| PY (1) | PY2243958A (https=) |
| TW (1) | TW202306570A (https=) |
| UY (1) | UY39796A (https=) |
| WO (1) | WO2022254362A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122764B2 (en) * | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4612128A4 (en) | 2022-11-04 | 2025-09-10 | Bristol Myers Squibb Co | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| WO2025230875A1 (en) * | 2024-04-29 | 2025-11-06 | Bristol-Myers Squibb Company | Compounds and their use for treatment of hemoglobinopathies |
| CN118598797A (zh) * | 2024-05-17 | 2024-09-06 | 诚达药业股份有限公司 | 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法 |
| WO2026002044A1 (zh) * | 2024-06-25 | 2026-01-02 | 标新生物医药科技(上海)有限公司 | 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9133161B2 (en) | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
| WO2017024019A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| EP3445765A4 (en) | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019079701A1 (en) | 2017-10-20 | 2019-04-25 | Dana-Farber Cancer Institute, Inc. | HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3765026A4 (en) | 2018-03-10 | 2021-12-22 | Yale University | BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| AU2019294835B2 (en) | 2018-06-29 | 2025-04-17 | Dana-Farber Cancer Institute, Inc. | Ligands to cereblon (CRBN) |
| US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| EP3814330A4 (en) | 2018-06-29 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| US12060366B2 (en) | 2018-06-29 | 2024-08-13 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
| BR122022012697B1 (pt) * | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AU2019391016B2 (en) * | 2018-12-03 | 2025-05-29 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| WO2021053555A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Glue degraders and methods of use thereof |
| CA3154386A1 (en) * | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
-
2022
- 2022-06-01 WO PCT/IB2022/055131 patent/WO2022254362A1/en not_active Ceased
- 2022-06-01 CN CN202280022964.9A patent/CN117062811A/zh active Pending
- 2022-06-01 BR BR112023024905A patent/BR112023024905A2/pt not_active Application Discontinuation
- 2022-06-01 UY UY0001039796A patent/UY39796A/es unknown
- 2022-06-01 TW TW111120484A patent/TW202306570A/zh unknown
- 2022-06-01 KR KR1020237045016A patent/KR20240013812A/ko not_active Ceased
- 2022-06-01 EP EP22731823.5A patent/EP4347580A1/en active Pending
- 2022-06-01 IL IL308094A patent/IL308094A/en unknown
- 2022-06-01 MX MX2023014327A patent/MX2023014327A/es unknown
- 2022-06-01 AU AU2022284366A patent/AU2022284366A1/en not_active Abandoned
- 2022-06-01 CA CA3215410A patent/CA3215410A1/en active Pending
- 2022-06-01 PY PY202202243958A patent/PY2243958A/es unknown
- 2022-06-01 CR CR20230614A patent/CR20230614A/es unknown
- 2022-06-01 PE PE2023003180A patent/PE20240657A1/es unknown
- 2022-06-01 AR ARP220101454A patent/AR126052A1/es not_active Application Discontinuation
- 2022-06-01 JP JP2023574412A patent/JP2024520654A/ja active Pending
- 2022-06-01 US US17/829,933 patent/US12103919B2/en active Active
-
2023
- 2023-11-29 CL CL2023003561A patent/CL2023003561A1/es unknown
- 2023-11-29 DO DO2023000261A patent/DOP2023000261A/es unknown
- 2023-11-29 JO JOJO/P/2023/0308A patent/JOP20230308A1/ar unknown
-
2024
- 2024-01-02 CO CONC2024/0000013A patent/CO2024000013A2/es unknown
- 2024-01-02 EC ECSENADI20244A patent/ECSP24000004A/es unknown
- 2024-09-03 US US18/823,254 patent/US20250026736A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230019617A1 (en) | 2023-01-19 |
| WO2022254362A1 (en) | 2022-12-08 |
| BR112023024905A2 (pt) | 2024-02-20 |
| US12103919B2 (en) | 2024-10-01 |
| IL308094A (en) | 2023-12-01 |
| JOP20230308A1 (ar) | 2023-11-29 |
| ECSP24000004A (es) | 2024-02-29 |
| CA3215410A1 (en) | 2022-12-08 |
| CO2024000013A2 (es) | 2024-01-25 |
| PE20240657A1 (es) | 2024-04-04 |
| AR126052A1 (es) | 2023-09-06 |
| JP2024520654A (ja) | 2024-05-24 |
| CN117062811A (zh) | 2023-11-14 |
| EP4347580A1 (en) | 2024-04-10 |
| AU2022284366A1 (en) | 2023-10-26 |
| CR20230614A (es) | 2024-02-01 |
| DOP2023000261A (es) | 2023-12-29 |
| MX2023014327A (es) | 2023-12-13 |
| UY39796A (es) | 2023-07-31 |
| PY2243958A (es) | 2023-01-20 |
| US20250026736A1 (en) | 2025-01-23 |
| KR20240013812A (ko) | 2024-01-30 |
| CL2023003561A1 (es) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4076650B1 (en) | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| TW202306570A (zh) | 3-(5-氧基)-1-側氧基異吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 | |
| KR102902295B1 (ko) | 피라졸로피리딘 유도체 및 이의 용도 | |
| US20250276964A1 (en) | Benzisoxazole Derivatives and Uses thereof | |
| IL270927A (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| CN116802182A (zh) | 吡唑并吡啶衍生物及其用途 | |
| CN116940571A (zh) | 苯并异噁唑衍生物及其用途 | |
| EA051403B1 (ru) | Производные пиразолопиридина и пути их применения | |
| BR112023018542B1 (pt) | Derivados de pirazolopiridina, e composição e combinação farmacêuticas | |
| BR122025004894A2 (pt) | Derivados de pirazolopiridina, seus usos, composição e combinação farmacêuticas, e kit |